intelliatx.com (NTLA) - Profit After Payment of Taxes

NTLA (intelliatx.com) - company brandmark

Intellia Therapeutics specializes in developing innovative treatments through genome modification. The market valuation of the asset is currently captured at -0.40, while the business relies on existing reserves and capital raising, as commercial products have not yet entered the market. The company's development depends on trial results rather than economic cycles. Geopolitical risks remain minimal due to compliance with Western standards.

Company Net Income: Intellia Corp (NTLA) for 07/04/2022 - 10/31/2026

Financial and market metric breakdowns for Intellia Therapeutics, Inc. (NTLA)

- stock quotes and analyst forecast:
Share Price Intellia Corp|NTLA - Consensus Target
- market capitalization indicators:
Market Value Intellia Corp|NTLA - Enterprise Value
- balance sheet net asset value indicators:
Net Asset Value per Share Intellia Therapeutics|NTLA - Company Book Value|Market Value to Book Value Ratio intelliatx.com|NTLA - Aggregate Company Assets
- debt burden and liquidity indicators:
Debt to Equity Intellia Therapeutics|NTLA - Long-Term Debt to Capital|Short-Term Debt to Capital Coefficient Intellia Therapeutics Inc|NTLA - Company Aggregate Debts|Debts to Book Capitalization Intellia Corp|NTLA - Company Long-Term Liabilities|Company Short-Term Loans and Borrowings Intellia Therapeutics|Intermediate Liquidity Ratio intelliatx.com
- company profitability and valuation multiples indicators:
NTLA - Net Profit
Fundamental valuation:Intellia Therapeutics
Finished products of Intellia

Investors assess business model resilience through the ability to generate real cash flow. For Intellia Therapeutics, which focuses on CRISPR therapies (NTLA-2001, NTLA-2002), this parameter reflects the balance between clinical trial costs and partnership payments. The company's net profitability measures the final remaining funds after deducting all operating and tax expenses. The trend along this curve determines the risk premium for holding the asset. The stability of this metric confirms the viability of the commercialization strategy.

Key competitors

Company Profit TEM|Net Income QGEN|IONS (ionispharma.com) - Profit After Payment of Taxes|Net Profit RGEN|RNA - Company Net Income|Company Net Income CRISPR Therapeutics Corp CRSP|GeneDx Corp - Company Net Income|RARE - Company Net Income|BEAM: Company Net Income|SRPT: Net Profit|TWST - Net Financial Result|TXG (10x Genomics Corp) - Net Profit|Net Profit Stoke Corp|Net Income BLFS (BioLife Solutions, Inc.)|WVE (wavelifesciences.com) - Final Profit|Maze Therapeutics - Net Income|Profit After Payment of Taxes SION (Sionna Therapeutics, Inc.)|Prime Medicine Corp - Net Profit|Final Profit TSHA (Taysha Corp)|QURE: Net Profit|Company Net Income meiragtx.com (MGTX)|Company Net Income REGENXBIO|SLDB: Final Profit|Net Profit OCGN|Net Profit PacBio Corp (PACB)|Company Net Income Benitec Biopharma Inc. BNTC|DSGN (designtx.com) - Profit After Tax|Rocket Pharmaceuticals, Inc. - Net Profit|Company Net Income 4DMT|LXEO (lexeotx.com) - Net Income|Korro Bio (KRRO) - Net Profit|Net Income EDIT|SLN (silence-therapeutics.com) - Profit After Payment of Taxes|Net Profit PRQR|Net Financial Result codexis.com|Net Profit SGMO (Sangamo)|NAUT - Net Income|MGX - Company Net Income|Net Financial Result Precision BioSciences Inc. DTIL|generationbio.com (GBIO) - Company Net Income|Company Profit BOLD|Net Income XCUR|IMNN (Celsion Corporation) - Profit After Payment of Taxes|Company Net Income Phio Pharmaceuticals (PHIO)|Company Net Income MBIO (mustangbio.com)|Net Profit RNAZ (TransCode Therapeutics, Inc.)|Net Profit Bionano Genomics Inc. BNGO|Applied DNA - Net Profit|BLUE (bluebird bio, Inc) - Company Profit|immunoprecise.com (IPA) - Company Net Income|Company Profit OMGA|OMIC (Singular Genomics) - Net Profit|Net Profit Regulus Therapeutics, Inc.|Net Profit SYRS|Net Financial Result Telesis Bio, Inc|Company Net Income TRACON Pharmaceuticals TCON|UBX: Company Profit